MADRIGAL PHARMACEUTICA

Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

31 1 2022 06:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st

30 1 2022 15:00:00 提供 Nasdaq GlobeNewswire

Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer

10 1 2022 07:00:01 提供 Nasdaq GlobeNewswire

Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

30 12 2021 07:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

23 11 2021 06:00:00 提供 Nasdaq GlobeNewswire

Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® Digital Experience 2021

12 11 2021 07:00:02 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results

04 11 2021 05:50:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

04 10 2021 05:50:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update

05 8 2021 05:50:00 提供 Nasdaq GlobeNewswire